Arcturus Therapeutics Holdings Inc reports a Return on Equity (ROE) of -41.11%.

What is ARCT's dividend yield?

Arcturus Therapeutics Holdings Inc offers a dividend yield of 0.00%.

What is ARCT's Quality Score?

Our AI rates ARCT's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ARCT?

Our AI Timing Score for ARCT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ARCT belong to?

Arcturus Therapeutics Holdings Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Arcturus Therapeutics Holdings Inc (ARCT) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-03 | FS: 2026-03-31)

ARCT AI Analysis Summary

Our AI summary for ARCT: Arcturus Therapeutics Holdings Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -41.11%, a dividend yield of 0.00%. Its financial Quality Score stands at 15/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ARCT

Arcturus Therapeutics Holdings Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 91

USD 6.00

0.22 (3.67%) Day Change

Watchlist Portfolio Compare Chart

0.02

D/E

-41.1%

ROE

-32.1%

ROA

0.00%

Div Yield

ARCTURUS THERAPEUTICS HOLDINGS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 6.00 Price 0.22 (3.67%) Day Change	NEWS SCORE: 91

ARCT, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

41%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	91
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	6.00
PBV / Sector	0.86 / 44,219.29 GREAT
Earning Per Share	-2.88

PE / Sector	N/A / 19.28
PEG or PE/Growth / Sector	N/A / 1.23
Average 1M Daily Value	2.95 M GREAT
Average 1W Daily Value	2.14 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-173.47 / 98.22
NPM Average (%) / Sector	-68.82 / -1,697.63
NPM Change Average (%) / Sector	-39.94 / 5,097.97
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-32.06 / 185,260.96
ROA Average (%) / Sector	-16.94 / 36,684.70
ROA Change Average (%) / Sector	-39.60 / 422,221.66
ROE (%) / Sector	-41.11 / 243,762.23
ROE Average (%) / Sector	-22.53 / 48,758.47
ROE Change Average (%) / Sector	-42.15 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.19

Registration Details

Analyze Date	2026-08-04 08:01:09
Symbol	ARCT
Name	ARCTURUS THERAPEUTICS HOLDINGS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	28.42 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	163.72 / 9,645.64

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 10285 Science Center Drive, San Diego, CA, United States, 92121

Phone: 858 900 2660

Website: https://arcturusrx.com

Employees: 106

Sector: Healthcare >> Biotechnology

Description: Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.